The tariff classification of HEC88473 Drug Product (also known as APL-18881) in dosage form, from China
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the HEC88473 drug product in dosage form will be 3002.15.0091, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Immunological products, put up in measured doses or in forms or packings for retail sale: Other.” The general rate of duty will be free.
- The applicable subheading for the HEC88473 drug product will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The rate of duty will be free.
Ruling text
In your letter dated July 4, 2025, you requested a tariff classification ruling. We apologize for the delay as the information was submitted to our laboratory for analysis. HEC88473 (also known as APL-18881) is a biological bi-specific protein targeting glucagon-like peptide-1 (GLP-1) and fibroblast growth factors 21 (FGF21). It is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and Alcohol Use Disorder (AUD).
In your letter, you stated the HEC88473 drug product will be imported in 15 mg, 30 mg and 45 mg pre-filled syringes for subcutaneous administration in clinical trials. According to our laboratory, HEC88473 is a modified immunological product.
The applicable subheading for the HEC88473 drug product in dosage form will be 3002.15.0091, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Immunological products, put up in measured doses or in forms or packings for retail sale: Other.” The general rate of duty will be free.
You also inquired about whether the imported HEC88473 drug product qualifies for duty free treatment as a prototype under subheading 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” You indicated that the HEC88473 drug product will be imported solely for use in Phase 2 clinical studies.
You also stated the HEC88473 drug product will be imported in approximately 10.98 kg in limited non-commercial quantities solely for use in clinical trials. You further indicate the imported product will not be sold and it is not subject to any quantitative restrictions, antidumping orders, or countervailing duty orders.
Based on the information presented, we find that HEC88473 drug product, qualifies for duty free treatment as a prototype under subheading 9817.85.01, HTSUS, provided that all of the conditions delineated in U.S. Note 7, Chapter 98, Subchapter XVII, Harmonized Tariff Schedule of the United States, (HTSUS) are satisfied.
The applicable subheading for the HEC88473 drug product will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The rate of duty will be free. The duties cited above are current as of this ruling’s issuance. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/.
This ruling does not address the applicability of any additional duties, taxes, fees, exactions and/or other charges, which may apply to the goods discussed herein. This includes, but is not limited to, tariffs and other duties as provided for in Subchapter III to Chapter 99, HTSUS.
Thus, for example, in addition to the classification stated above, the merchandise covered by this ruling may also need to be reported with either the Chapter 99 provision under which an additional tariff applies or one of the Chapter 99 provisions covering exceptions to such tariffs.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N350948).